Deciphera Pharmaceuticals, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2027-02: Study NCT07818070; Company role Collaborator; Phase Phase 3; Status Not yet recruiting.
- 2027-01: Study NCT07825402; Company role Collaborator; Phase Phase 3; Status Not yet recruiting.
- 2026-09: Study NCT07744802; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2026-06-12: Study NCT07104032; Company role Collaborator; Phase Phase 3; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2027-02 | NCT07818070 A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma | Collaborator Lead: Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Gastric Cancer; Esophagogastric Junction Cancer; Esophageal Adenocarcinoma | 600 | 2031-01 |
| 2027-01 | NCT07825402 A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) | Collaborator Lead: Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Multiple System Atrophy, Parkinson Variant | 486 | 2029-10 |
| 2026-09 | NCT07744802 Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants | Lead sponsor | Phase 1 | Recruiting | Healthy Male Participants | 20 | 2026-12 |
| 2026-06-12 | NCT07104032 IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | Collaborator Lead: Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Primary Central Nervous System Lymphoma | 132 | 2029-12 |
| 2026-06-05 | NCT07539090 Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) | Lead sponsor | Phase 1 | Recruiting | Healthy Participants | 24 | 2026-10 |
| 2026-05-25 | NCT07429266 INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) | Collaborator Lead: Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Polycythemia Vera | 250 | 2031-01 |
| 2025-11-20 | NCT07158411 Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) | Lead sponsor | Phase 1 | Completed | Healthy Participants | 22 | 2026-01-30 |
| 2025-10-31 | NCT07158398 Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate | Lead sponsor | Phase 1 | Completed | Healthy Participants | 20 | 2025-12-08 |
| 2025-09-03 | NCT07075471 MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib | Lead sponsor | Observational | Recruiting | Tenosynovial Giant Cell Tumor | 100 | 2027-09 |
| 2025-08-27 | NCT06966024 Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Lead sponsor | Phase 1 | Recruiting | Renal Cell Carcinoma; Urothelial Carcinoma; Castration-resistant Prostate Cancer | 60 | 2029-02 |
| 2024-12-10 | NCT06630234 A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Lead sponsor | Phase 1, Phase 2 | Recruiting | Gastrointestinal Stromal Tumor (GIST) | 120 | 2028-05 |
| 2024-11-21 | NCT06619561 A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Lead sponsor | Phase 2 | Recruiting | Chronic Graft-Versus-Host Disease (cGVHD) | 48 | 2029-10 |
| 2024-05-14 | NCT06287463 Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumor; RAF Mutation; RAS Mutation; NF1 Mutation; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Melanoma; BRAF Gene Mutation; CRAF Gene Mutation; Castration-Resistant Prostate Cancer (CRPC) | 29 | 2026-02-13 |
| 2023-12-13 | NCT05734105 A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | Lead sponsor | Phase 3 | Active not recruiting | GIST | 54 | 2028-12 |
| 2023-09-28 | NCT05957367 A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Lead sponsor | Phase 1, Phase 2 | Recruiting | GIST | 94 | 2029-03 |
| 2021-11 | NCT05080621 Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Gastrointestinal Stromal Tumors | 0 | 2027-05 |
| 2021-10-14 | NCT05059262 Study of Vimseltinib for Tenosynovial Giant Cell Tumor | Lead sponsor | Phase 3 | Active not recruiting Results posted | Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor, Diffuse; Tenosynovial Giant Cell Tumor, Localized | 123 | 2028-07 |
| 2021-09-22 | NCT04530981 A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST | Lead sponsor | Phase 1 | Completed | GIST - Gastrointestinal Stromal Tumor | 13 | 2024-07-29 |
| 2021-06-15 | NCT04892017 Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Lead sponsor | Phase 1 | Terminated | Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor | 91 | 2026-03-30 |
| 2019-02-08 | NCT03673501 A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Lead sponsor | Phase 3 | Active not recruiting Results posted | Gastrointestinal Stromal Tumors | 453 | 2026-12 |
| 2019-01-02 | NCT03717415 A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Locally Advanced or Metastatic Solid Tumor | 70 | 2022-11-01 |
| 2018-10-25 | NCT03601897 A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Locally Advanced or Metastatic Solid Tumor | 177 | 2022-05-23 |
| 2018-02-27 | NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies | Lead sponsor | Phase 3 | Completed Results posted | Gastrointestinal Stromal Tumors | 129 | 2022-05-11 |
| 2017-02-16 | NCT03069469 Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Advanced Malignant Neoplasm; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor; Tenosynovial Giant Cell Tumor, Diffuse | 120 | 2028-08 |
| 2016-07 | NCT02824575 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Collaborator Lead: Montefiore Medical Center | Phase 1 | Terminated | Breast Cancer; Breast Adenocarcinoma; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Recurrent Breast Carcinoma; Stage IV Breast Cancer | 28 | 2021-12-27 |
| 2015-11 | NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Lead sponsor | Phase 1 | Completed | Gastrointestinal Stromal Tumors; Advanced Systemic Mastocytosis; Advanced Cancers | 282 | 2022-04-29 |
| 2014-06 | NCT02228811 A Study of DCC-2701 in Participants With Advanced Solid Tumors | Lead sponsor | Phase 1 | Terminated | Locally Advanced Tumors; Metastatic Solid Tumors; Cancers With MET Genomic Alterations; Cancers With TRK Genomic Alterations | 44 | 2018-01 |
| 2009-03 | NCT00827138 Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | Lead sponsor | Phase 1 | Completed | Chronic Myeloid Leukemia | 57 | 2013-01 |
| NCT04148092 Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | Lead sponsor | Expanded_access | Approved for marketing | GIST - Gastrointestinal Stromal Tumor |